MicroRNA‑155 promotes apoptosis of colonic smooth muscle cells and aggravates colonic dysmotility by targeting IGF‑1

Shen,Xiaoxue; Zhao,Zhibin; Yang,Bin

doi:10.3892/etm.2020.8485

MicroRNA‑155 promotes apoptosis of colonic smooth muscle cells and aggravates colonic dysmotility by targeting IGF‑1

Authors:
- Xiaoxue Shen
- Zhibin Zhao
- Bin Yang
View Affiliations

Affiliations: Department of Gastroenterology, Jiangsu Taizhou People's Hospital, Taizhou, Jiangsu 225300, P.R. China
Published online on: February 4, 2020 https://doi.org/10.3892/etm.2020.8485
Pages: 2725-2732

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colonic dysmotility as a complication of diabetes affects public health; however, the underlying molecular mechanisms have remained elusive. Insulin‑like growth factor‑1 (IGF‑1) was previously demonstrated to prevent apoptosis of colonic smooth muscle cells (SMCs) and alleviate colonic dysmotility in diabetic rats. However, the regulatory mechanisms upstream of IGF‑1 in colonic dysmotility have remained to be determined. The present study reports on microRNA‑155 (miR‑155), initially identified using bioinformatics, as a direct upstream regulator of IGF‑1. In colonic SMCs, miR‑155 negatively regulated IGF‑1 expression at the post‑transcriptional level, as identified through ectopic overexpression and knockdown experiments. A luciferase reporter assay further demonstrated that miR‑155 inhibits IGF‑1 through binding to its 3'‑untranslated region. Furthermore, overexpression of miR‑155 led to increased apoptosis of colonic SMCs and a decrease in the thickness of colonic smooth muscle tissues of diabetic mice, indicating miR‑155 aggravates colonic dysmotility. By contrast, knockdown of miR‑155 induced the opposite effect. Overall, the results of the present study suggest a role of miR‑155 in colonic dysmotility, thereby providing a novel therapeutic target.

View Figures

View References

1	Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P and Zinman B: DiabetesControl and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 353:2643–2653. 2005.PubMed/NCBI View Article : Google Scholar
2	Severino P, D'Amato A, Netti L, Pucci M, De Marchis M, Palmirotta R, Volterrani M, Mancone M and Fedele F: Diabetes mellitus and ischemic heart disease: The role of ion channels. Int J Mol Sci. 19(E802)2018.PubMed/NCBI View Article : Google Scholar
3	Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP and Horowitz M: Prevalence of gastrointestinal symptoms associated with diabetes mellitus: A population-based survey of 15,000 adults. Arch Intern Med. 161:1989–1996. 2001.PubMed/NCBI View Article : Google Scholar
4	Samsom M, Vermeijden JR, Smout AJ, Van Doorn E, Roelofs J, Van Dam PS, Martens EP, Eelkman-Rooda SJ and Van Berge-Henegouwen GP: Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: A prospective study in unselected diabetic patients. Diabetes Care. 26:3116–3122. 2003.PubMed/NCBI View Article : Google Scholar
5	Rodrigues ML and Motta ME: Mechanisms and factors associated with gastrointestinal symptoms in patients with diabetes mellitus. J Pediatr (Rio J). 88:17–24. 2012.PubMed/NCBI View Article : Google Scholar
6	Sanders KM, Koh SD, Ro S and Ward SM: Regulation of gastrointestinal motility-insights from smooth muscle biology. Nat Rev Gastroenterol Hepatol. 9:633–645. 2012.PubMed/NCBI View Article : Google Scholar
7	Sun M, Wang F and Feng P: Insulin-like growth factor-1 inhibits colonic smooth muscle cell apoptosis in diabetic rats with colonic dysmotility. Regul Pept. 194-195:41–48. 2014.PubMed/NCBI View Article : Google Scholar
8	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.PubMed/NCBI View Article : Google Scholar
9	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004.PubMed/NCBI View Article : Google Scholar
10	John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. PLoS Biol. 2(e363)2004.PubMed/NCBI View Article : Google Scholar
11	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009.PubMed/NCBI View Article : Google Scholar
12	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009.PubMed/NCBI View Article : Google Scholar
13	Lujambio A and Lowe SW: The microcosmos of cancer. Nature. 482:347–355. 2012.PubMed/NCBI View Article : Google Scholar
14	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.PubMed/NCBI View Article : Google Scholar
15	Miao S, Mao X, Pei R, Song K, Lv Y, Jiang H, Li B, Yang X, Xiu C, Meng H and Sun J: MiR-448 inhibits laryngeal cancer metastasis by repressing AEG-1 expression. Int J Clin Exp Med. 11:1587–1596. 2018.PubMed/NCBI View Article : Google Scholar
16	Cao M, Bai L, Wang D, Zhai Q, Li Y, Hai J and Wang W: miRNA-33 expression and its mechanism in patients and model rats with type 2 diabetic nephropathy. Int J Clin Exp Med. 11:1661–1668. 2018.
17	Gao Y, Liu Z, Ding Z, Hou S, Li J and Jiang K: MicroRNA-155 increases colon cancer chemoresistance to cisplatin by targeting forkhead box O3. Oncol Lett. 15:4781–4788. 2018.PubMed/NCBI View Article : Google Scholar
18	Liu J, Chen Z, Xiang J and Gu X: MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro. Oncol Lett. 15:5561–5568. 2018.PubMed/NCBI View Article : Google Scholar
19	Gao J, Zhao G, Li W, Zhang J, Che Y, Song M, Gao S, Zeng B and Wang Y: MiR-155 targets PTCH1 to mediate endothelial progenitor cell dysfunction caused by high glucose. Exp Cell Res. 366:55–62. 2018.PubMed/NCBI View Article : Google Scholar
20	Pathak S, Grillo AR, Scarpa M, Brun P, D'Incà R, Nai L, Banerjee A, Cavallo D, Barzon L, Palù G, et al: MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. Exp Mol Med. 47(e164)2015.PubMed/NCBI View Article : Google Scholar
21	Dweep H and Gretz N: miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 12(697)2015.PubMed/NCBI View Article : Google Scholar
22	Dahan D, Ekman M, Larsson-Callerfelt AK, Turczyńska K, Boettger T, Braun T, Swärd K and Albinsson S: Induction of angiotensin-converting enzyme after miR-143/145 deletion is critical for impaired smooth muscle contractility. Am J Physiol Cell Physiol. 307:C1093–C1101. 2014.PubMed/NCBI View Article : Google Scholar
23	Nijhuis A, Biancheri P, Lewis A, Bishop CL, Giuffrida P, Chan C, Feakins R, Poulsom R, Di Sabatino A, Corazza GR, et al: In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. Clin Sci (Lond). 127:341–350. 2014.PubMed/NCBI View Article : Google Scholar
24	Park M, Choi S, Kim S, Kim J, Lee DK, Park W, Kim T, Jung J, Hwang JY, Won MH, et al: NF-kB-responsive miR-155 induces functional impairment of vascular smooth muscle cells by downregulating soluble guanylyl cyclase. Exp Mol Med. 51(17)2019.PubMed/NCBI View Article : Google Scholar
25	Zhao XS, Han B, Zhao JX, Tao N and Dong CY: MiR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1. Eur Rev Med Pharmacol Sci. 23:1030–1037. 2019.PubMed/NCBI View Article : Google Scholar
26	Wang C, Zhang C, Liu L, A X, Chen B, Li Y and Du J: Macrophage-derived mir-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury. Mol Ther. 25:192–204. 2017.PubMed/NCBI View Article : Google Scholar
27	Ji H, Tian D, Zhang B, Zhang Y, Yan D and Wu S: Overexpression of miR-155 in clear-cell renal cell carcinoma and its oncogenic effect through targeting FOXO3a. Exp Ther Med. 13:2286–2292. 2017.PubMed/NCBI View Article : Google Scholar
28	Li DP, Fan J, Wu YJ, Xie YF, Zha JM and Zhou XM: MiR-155 up-regulated by TGF-β promotes epithelial-mesenchymal transition, invasion and metastasis of human hepatocellular carcinoma cells in vitro. Am J Transl Res. 9:2956–2965. 2017.PubMed/NCBI
29	Liu F, Song D, Wu Y, Liu X, Zhu J and Tang Y: MiR-155 inhibits proliferation and invasion by directly targeting PDCD4 in non-small cell lung cancer. Thorac Cancer. 8:613–619. 2017.PubMed/NCBI View Article : Google Scholar